Targeted drug trial offers hope for children with aggressive brain cancer
NCT ID NCT06333899
Summary
This study is testing a targeted drug called lorlatinib in children and young adults (ages 1-21) newly diagnosed with aggressive brain tumors (high-grade gliomas) that have specific genetic changes called ALK or ROS1 fusions. The main goals are to see if the drug can control the tumor and to check its safety, either given alone or alongside standard chemotherapy or after radiation. It's an early-phase study that will enroll up to 15 patients to gather initial data.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ann & Robert H. Lurie Children's Hospital of Chicago
NOT_YET_RECRUITINGChicago, Illinois, 60611, United States
Contact Email: •••••@•••••
-
Children's Hospital Colorado
NOT_YET_RECRUITINGAurora, Colorado, 80045, United States
Contact Email: •••••@•••••
-
Children's Hospital of Philadelphia
NOT_YET_RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Email: •••••@•••••
-
Children's National Medical Center
NOT_YET_RECRUITINGWashington D.C., District of Columbia, 20010, United States
Contact Email: •••••@•••••
-
Cincinnati Children's Hospital Medical Center
RECRUITINGCincinnati, Ohio, 45229, United States
Contact Email: •••••@•••••
-
Dana-Farber Cancer Institute
NOT_YET_RECRUITINGBoston, Massachusetts, 02215, United States
Contact Email: •••••@•••••
-
Duke University Health System
NOT_YET_RECRUITINGDurham, North Carolina, 27708, United States
Contact Email: •••••@•••••
-
Hopp Children's Cancer Center at NCT Heidelberg (KiTZ)
NOT_YET_RECRUITINGHeidelberg, Baden-Wurttemberg, 69120, Germany
Contact Email: •••••@•••••
-
Montreal Children's Hospital
NOT_YET_RECRUITINGMontreal, Quebec, H4A3J1, Canada
Contact Email: •••••@•••••
-
Nationwide Children's Hospital
NOT_YET_RECRUITINGColumbus, Ohio, 43235, United States
Contact Email: •••••@•••••
-
Perth Children's Hospital
NOT_YET_RECRUITINGPerth, Western Australia, 6000, Australia
Contact Email: •••••@•••••
-
Princess Máxima Center
NOT_YET_RECRUITINGUtrecht, 3720, Netherlands
Contact Email: •••••@•••••
-
Queensland Children's Hospital
NOT_YET_RECRUITINGSouth Brisbane, Queensland, 4101, Australia
Contact Email: •••••@•••••
-
Seattle Children's Hospital
NOT_YET_RECRUITINGSeattle, Washington, 98105, United States
Contact Email: •••••@•••••
-
Starship Children's Hospital
NOT_YET_RECRUITINGAuckland, Grafton, 1023, New Zealand
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sydney Children's Hospital
NOT_YET_RECRUITINGRandwick, New South Wales, 2031, Australia
Contact Email: •••••@•••••
-
Texas Children's Hospital
NOT_YET_RECRUITINGHouston, Texas, 77030, United States
Contact Email: •••••@•••••
-
The Hospital for Sick Children (SickKids)
NOT_YET_RECRUITINGToronto, Ontario, M5G1X8, Canada
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.